PUBLISHER: Grand View Research | PRODUCT CODE: 2089710
PUBLISHER: Grand View Research | PRODUCT CODE: 2089710
The global psoriasis drugs market size was valued at USD 23.27 billion in 2025 and is projected to grow from USD 25.70 billion in 2026 to USD 54.88 billion by 2033, at a CAGR of 11.4% from 2026 to 2033. North America psoriasis drugs market held the largest share of 38.3% of the global market in 2025. The psoriasis drugs market is witnessing strong growth driven by advances in immunomodulators, increasing adoption of biologic therapies, and favorable reimbursement support across developed healthcare markets.
Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases
Continuous research and development activities are contributing to treatment innovation, particularly for moderate to severe psoriasis cases, thereby supporting demand for targeted therapies. A major market trend is the increasing competition from biosimilars, which is reshaping the competitive landscape for established biologics and improving treatment accessibility. Growing acceptance of biosimilars among healthcare providers and payers is helping reduce herapy costs and expand patient access, especially in cost-sensitive markets. In addition, the market continues to shift toward advanced interleukin inhibitors and targeted oral therapies due to their improved efficacy, longer treatment durability, and favorable clinical outcomes compared to conventional systemic treatments.The market is also experiencing a strong shift toward precision-based psoriasis management, supported by the increasing preference for targeted biologics and next-generation oral therapies. Interleukin inhibitors targeting IL-17 and IL-23 pathways continue to gain significant commercial traction due to their high skin clearance rates, rapid onset of action, and sustained therapeutic response. Pharmaceutical companies are actively focusing on lifecycle management strategies, label expansions, and development of improved formulations to strengthen product positioning in the competitive immunology segment. In addition, increasing physician awareness regarding long-term disease management and comorbidity reduction is contributing to higher adoption of advanced psoriasis therapeutics.
Rising prevalence of chronic inflammatory skin disorders and increasing demand for long-term disease management therapies continue to support the growth of the psoriasis drugs market. The market is benefiting from higher adoption of advanced biologics and targeted therapies that offer improved efficacy, better symptom control, and enhanced patient outcomes compared to conventional treatments. In addition, increasing healthcare expenditure, expanding access to specialty dermatology care, and growing awareness regarding early diagnosis and treatment are further contributing to market expansion. Continuous product innovation, broader biosimilar availability, and ongoing regulatory support for novel psoriasis therapies are expected to sustain competitive development and create favorable growth opportunities for the market during the forecast period.
Global Psoriasis Drugs Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global psoriasis drugs market report based on class, treatment, route of administration, distribution channel, and region: